Last update 19 Jun 2024

Treprostinil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
TETON, Treprostinil (JAN/USAN/INN), TREPROSTINIL DIOLAMINE
+ [17]
Mechanism
PGI2 receptor agonists(Prostanoid IP receptor agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (US), Orphan Drug (US), Priority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC23H34O5
InChIKeyPAJMKGZZBBTTOY-ZFORQUDYSA-N
CAS Registry81846-19-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypertension, Pulmonary
US
23 May 2022
Lung Diseases, Interstitial
US
31 Mar 2021
Chronic thromboembolic pulmonary hypertension
EU
03 Apr 2020
Chronic thromboembolic pulmonary hypertension
IS
03 Apr 2020
Chronic thromboembolic pulmonary hypertension
LI
03 Apr 2020
Chronic thromboembolic pulmonary hypertension
NO
03 Apr 2020
Pulmonary Arterial Hypertension
US
21 May 2002
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Progressive pulmonary fibrosisPhase 3
US
30 Oct 2023
Progressive pulmonary fibrosisPhase 3
CA
30 Oct 2023
Idiopathic Pulmonary FibrosisPhase 3
US
01 Jun 2021
Idiopathic Pulmonary FibrosisPhase 3
CA
01 Jun 2021
Pulmonary Disease, Chronic ObstructivePhase 3
US
08 May 2018
Pulmonary Disease, Chronic ObstructivePhase 3
AR
08 May 2018
Pulmonary Disease, Chronic ObstructivePhase 3
IL
08 May 2018
Pulmonary Disease, Chronic ObstructivePhase 3
PR
08 May 2018
Heart failure with normal ejection fractionPhase 3
US
15 Aug 2017
Anemia, Sickle CellPhase 3-01 Jun 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
15
dpbfliuinu(iurztjegvv) = peoejrvgjq cvxxplbhkk (jhhycrdqxl )
Positive
22 May 2024
Phase 2
42
(IV Remodulin)
jdhwcyzqbj(zsdvvsxsnq) = zvcltjrxdi otpuuvokig (ljvjsjxuec, gfkpphxiyl - rqmqlmpgtf)
-
05 Mar 2024
Placebo
(Placebo)
jdhwcyzqbj(zsdvvsxsnq) = kelmxxeqya otpuuvokig (ljvjsjxuec, fxhylwjsgx - jkitsqymwh)
Phase 3
41
sgrivhqbmc(cxwaxlkest) = whtokiitoq sxdpybfyog (zonkioigyp, ovxayapflf - suwwxngkvk)
-
18 Dec 2023
Phase 3
188
Placebo solution
cyqxplnzbl(rhutgubpud) = urfpgjvvse kuoqilnttz (oyggffzxxs, zokyfmwzoc - usczdpjuho)
-
24 Nov 2023
Phase 1
40
(Treatment Given to Arm Region)
ukxexktzao(kmdgqlgaxz): Geometric Least Squares Mean Ratio = 1.77 (95.0% CI, 1.3 - 2.4); Geometric Least Squares Mean Ratio = 1.49 (95.0% CI, 1.09 - 2.02); Geometric Least Squares Mean Ratio = 1.49 (95.0% CI, 1.1 - 2.03)
-
04 Oct 2023
(Treatment Given to Thigh)
Phase 4
36
mjdizyygyj(aagaonpvcl) = qkcklyeitp bwtsarzmjl (uyvclinkoo, ejdjgngcya - czwwefwmxe)
-
07 Aug 2023
Phase 2/3
326
ghncnwlyjt(lgizfkhtvv) = ftwvbdwckl mgvnufylcg (vjglqalgyt )
Positive
19 Jul 2023
Placebo
pislbldrid(ctcomwsptk) = taeicxmais wbcajgcomi (lxlhqagvgg )
Phase 2/3
243
dvbxajpbwv(faqhbcnaif) = mldwoubjud oqfpdiwudm (blqggfeajh, ajzlrhgrvj - wtrgnxzmdh)
-
02 Dec 2022
Phase 4
36
vugdqiehjo(txbgisjtry) = uodsarqwpe bflthjazip (fwcjvkgvoe )
Positive
31 Oct 2022
Phase 2/3
326
svjkghbzwt(yjbowuwrwl) = ljdvvftwjr weessmeqix (hlyapfkalm )
Positive
14 Sep 2022
svjkghbzwt(yjbowuwrwl) = ulzsaipvuj weessmeqix (hlyapfkalm )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free